Advagene Biopharma Co., Ltd.
About Advagene
Milestone
Management Team
Board of Directors
R&D PIPELINE
NEW DRUG PEPLINE
Intranasal Vaccines
Airway allergy immunotherapy
Covid-19-immunitytherapy
Other vaccine applications
News
News
Press Releases
Partnerships and Collaborators
Investors
Catalogs
公開資訊觀測站
繁體中文
English
简体中文
Contact Us
Home
News
News
The first subject participated in cohort 3(high-dose group) of Ib/IIa trial of allergic rhinitis immunotherapy.
The first subject participated in cohort 3(high-dose group) of Ib/IIa trial of allergic rhinitis immunotherapy.
The first subject participated in cohort 3(high-dose group) of Ib/IIa trial of allergic rhinitis immunotherapy.
2020-04-08
Back
繁體中文
English
简体中文